Abstract:Hossein Kazemian, 1 Jalil Kardan-Yamchi, 2 Abbas Bahador, 1 Shadi Khonsari, 3 Mahshid Nasehi, 4 Gholamreza Hamzehloo, 5 Farzam Vaziri, 6 Mohammad Reza Salehi, 7 Mohammad Mehdi Feizabadi 1, 8 1 Department of Medical Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; 2 Division of Microbiology, Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran; 3 Natural Science Department, School of Science and Technology, Middlesex University, London, UK; 4 Department of Epidemiology and Biostatistics, Iran University of Medical Sciences, Tehran, Iran; 5 Tehran Regional Reference Laboratory for Tuberculosis, Tehran, Iran; 6 Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran; 7 Department of Infectious Disease, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran; 8 Thoracic Research Center, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran Correspondence: Mohammad Mehdi Feizabadi Department of Medical Microbiology, School of Medicine, Tehran University of Medical Sciences, Poursina Street, Engelab-e-Eslami Avenue, Tehran, Iran Tel +989121767987 Fax +982188955810 Email mfeizabadi@tums.ac.ir Background: Successful treatment of tuberculosis depends on early diagnosis and use of appropriate drug susceptibility testing in a timely manner. In the present study, LPA efficacy was assayed in detection and drug susceptibility testing of pulmonary tuberculosis in comparison to available methods in Iran and phylogenetic analyses of isolated cases carried out by MIRU-VNTR. Methods: This study was conducted at the Tehran Regional Reference Laboratory for Tuberculosis. All sputum specimens were subjected to smear, culture, and drug susceptibility testing (DST), GeneXpert, and LPA. Finally, 15-locus-based MIRU-VNTR was used for molecular genotyping. Results: From a total of 920 sputum specimens, 6.08% (n=56) were identified as MTBC by culture, 6.8% (n=63) by GeneXpert, and 6.5% (n=60) by LPA. Phenotype DST and LPA methods confirmed the resistance of 4 and 14 specimens to rifampin (RIF) and isoniazid (INH); two cases were considered as multidrug-resistant (MDR). Using GeneXpert, four cases were identified as RIF-resistant. Based on LPA results, inhA and katG mutations were detected in 100% and 21.4% of INH-resistant cases, respectively. All 56 culture positive Mycobacterium tuberculosis isolates were placed in 29 different clusters using MIRU-VNTR genotyping. Two MDR-TB, 2 RIF mono-resistant, and 12 INH mono-resistant cases were placed in different clusters. Conclusion: LPA is an appropriate method for early detection and accurate diagnosis of TB and drug-resistant cases that makes it possible to distinguish INH mono-resistant cases from MDR cases in Iran. Keywords: tuberculosis, line probe assay, early diagnosis, drug resistance, mutation

Evaluation of rapid diagnostic tests and assessment of risk factors in drug-resistant pulmonary tuberculosis

Performance Comparison of Three Rapid Tests for the Diagnosis of Drug-Resistant Tuberculosis

Synergy of Xpert (MTB/RIF) and Line probe assay for detection of rifampicin resistant strains of Mycobacterium tuberculosis

Xpert MTB/XDR assay: rapid TB drug resistance detection

Performance evaluation of the Xpert MTB/XDR test for the detection of drug resistance to Mycobacterium tuberculosis among people diagnosed with tuberculosis in South Africa

Diagnosis of drug-resistant tuberculosis: reliability and rapidity of detection

Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis.

Diagnostic challenges and Gene-Xpert utility in detecting Mycobacterium tuberculosis among suspected cases of Pulmonary tuberculosis

Diagnostic utility of GeneXpert MTB/RIF assay versus conventional methods for diagnosis of pulmonary and extra-pulmonary tuberculosis

Comparison of GeneXpert and line probe assay for detection of Mycobacterium tuberculosis and rifampicin-mono resistance at the National Tuberculosis Reference Laboratory, Kenya

Evaluation of GeneNAT Real-Time Polymerase Chain Reaction Analyzer and Pre-loaded Chip-Based Mycobacterium tuberculosis and Multidrug-Resistant Tuberculosis Detection in the Diagnosis of Pulmonary Tuberculosis

Rapid Molecular Assays for the Diagnosis of Drug-Resistant Tuberculosis

To Test or Not? Xpert MTB/RIF as an Alternative to Smear Microscopy to Guide Line Probe Assay Testing for Drug-Resistant Tuberculosis

Detection of multidrug resistance and extensively drug resistance among smear-negative extrapulmonary tuberculosis cases in a reference laboratory

Efficacy Of Line Probe Assay In Detection Of Drug-Resistant Pulmonary Tuberculosis In Comparison With GeneXpert And Phenotypic Methods In Iran And Genetic Analysis Of Isolates By MIRU-VNTR

Evaluation of Diagnostic Methods and Rifampicin Resistance in Pulmonary Tuberculosis: A Hospital-Based Study

Clinical value of GeneXpert MTB/RIF in rapid diagnosis of pulmonary tuberculosis and detection of rifampicin-resistance

Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study

Non-actionable Results, Accuracy, and Effect of First- and Second-line Line Probe Assays for Diagnosing Drug-Resistant Tuberculosis, Including on Smear-Negative Specimens, in a High-Volume Laboratory

Tuberculosis with discordant drug resistance patterns- A diagnostic dilemma

Molecular Approaches for Detection of the Multi-Drug Resistant Tuberculosis (MDR-TB) in Bangladesh.